The “hyping” of new forms of treatment for cancer

In a newly published article on the STAT web site, two clinicians at Oregon Health and Science University argue that the benefits of immunotherapy in the treatment of cancer are being greatly over-“hyped”. … READ MORE …

Laboratory data suggests carvacrol may have anti-prostate cancer activity

A presentation at the Experimental Biology 2012 meeting in San Diego this week has suggested that carvacrol (a chemical found in the herb oregano) has activity against prostate cancer cells in laboratory tests. We hasten to point out that this sort of test does not necessarily mean that carvacrol would ever be shown to have activity against prostate cancer in man. … READ MORE …

Another “breakthrough” in prostate cancer research? Hmmm?

In a hype-laden media release from the 16th World Congress on Advances in Oncology and 14th International Symposium on Molecular Medicine ongoing in Rhodes, Greece, comes another of those “breakthrough” claims with no actual data. … READ MORE …

The monoclonal antibody F77 and media “over-hype”

“Found, the super molecule to kill prostate cancer cells,” trumpeted the MailOnline. And worse still, “A miracle molecule has been discovered that offers the hope of saving men with currently incurable prostate cancer,” screamed the Press Association. … READ MORE …

Leonard Salz, MD, on hope and hype

Some regular readers of the cancer literature may want to see an article just published in the Journal of Clinical Oncology by Leonard Salz, MD (a world-famous colorectal cancer specialist) on the way in which language affects perceptions in the world of cancer communication.

The article basically says we all need to be more specific about how we explain things like the difference between “significant” and “statistically significant” or what we mean by “toxicity was tolerable” in a clinical trial. And Dr. Salz makes many good points that The “New” Prostate Cancer InfoLink will do its best to take to heart!